AVITA Medical Appoints Cary Vance As Interim CEO

AVITA Medical Inc. (RCEL) announced a leadership transition, appointing Chairman Cary Vance as Interim CEO following Jim Corbett's departure, while initiating a search for a permanent successor. Concurrently, the company reported preliminary third-quarter 2025 revenue of approximately $17 million and secured a waiver for its Q3 2025 trailing 12-month net revenue covenant with OrbiMed, with ongoing discussions to redefine future terms. AVITA Medical plans to provide an update on annual guidance during its November 6, 2025, Q3 earnings call.

Analysis

AVITA Medical Inc. (RCEL) announced an immediate leadership transition, with Chairman Cary Vance appointed Interim CEO following Jim Corbett's departure. This move, coupled with the initiation of a search for a permanent CEO including both internal and external candidates, introduces a period of management uncertainty. The appointment of Jan Stern Reed as Lead Independent Director aims to bolster board oversight during this transition.

Financially, the company reported preliminary third-quarter 2025 revenue of approximately $17 million. More critically, AVITA secured a waiver from OrbiMed for its Q3 2025 trailing 12-month net revenue covenant, indicating a potential breach or concern regarding financial performance. Discussions are ongoing to redefine future covenants, suggesting continued financial scrutiny and potential restructuring of debt terms.

The company is currently assessing its annual guidance and plans to provide an update during its Q3 earnings call on November 6, 2025. This delay, combined with the covenant waiver and leadership change, contributes to a moderately negative sentiment and an uncertain tone surrounding RCEL's near-term operational and financial outlook, as indicated by the provided signals.

Key Decisions for Investors

• Investors should closely monitor the ongoing CEO search and the company's Q3 earnings call on November 6, 2025, for updated annual guidance and details on the OrbiMed covenant discussions, given the current financial uncertainty.
• Evaluate the implications of the preliminary $17 million Q3 revenue and the secured covenant waiver, as these suggest potential operational challenges and increased financial risk.
• Consider holding or reducing exposure until greater clarity emerges regarding leadership, financial covenants, and future guidance.